Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.77 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.77 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.77 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.77 |
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.48 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.48 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.48 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL27792685 | 0.97 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1007031 | 0.97 | FFAR3 (0.81) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL27852497 | 0.94 | FFAR3 (0.77) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL28552593 | 0.92 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL7002483 | 0.91 | — | — | |
| Butyric Acid SCHEMBL26688 | 0.91 | — | — | |
| Butyric Acid SCHEMBL11058240 | 0.91 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11242942 | 0.91 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL967761 | 0.91 | — | — | |
| Butyric Acid SCHEMBL11791723 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113574097-B | Biodegradable resin particles, biodegradable resin particle group containing the same, and use thereof | 积水化成品工业株式会社 | 2024-08-09 | — | — | CN | disclosed |
| CN-113677759-B | Biodegradable resin particles and external preparation containing same | 积水化成品工业株式会社 | 2023-05-02 | — | — | CN | disclosed |
| EP-2181979-B1 | Conversion of a multihydroxylated aliphatic hydrocarbon or ester thereof to a chlorohydrin | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8926916-B2 | Process and apparatus for recovery of dichlorohydrins via codistillation | DOW GLOBAL TECHNOLOGIES LLC (US) | 2015-01-06 | — | — | US | disclosed |
| US-8845972-B2 | Process and apparatus for efficient recovery of dichlorohydrins | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8664453-B2 | Multi-stage process and apparatus for recovering dichlorohydrins | DOW GLOBAL TECHNOLOGIES INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8629305-B2 | Process and apparatus for azeotropic recovery of dichlorohydrins | DOW GLOBAL TECHNOLOGIES INC (US) | 2014-01-14 | — | — | US | disclosed |
| US-8586802-B2 | Multi-stage process and apparatus for recovering dichlorohydrins | DOW GLOBAL TECHNOLOGIES LLC | 2013-11-19 | — | — | US | disclosed |
| US-20130259766-A1 | PPROCESS AND APPARATUS FOR EFFECIENT RECOVERY OF DICHLOROHYDRINS | BLUE CUBE IP LLC | 2013-10-03 | — | — | US | disclosed |
| US-20130202497-A1 | PROCESS AND APPARATUS FOR RECOVERY OF DICHLOROHYDRINS VIA CODISTILLATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-20080045728-A1 | Conversion of a Multihydroxylated-Aliphatic Hydrocarbon or Ester Thereof to a Chlorohydrin | BLUE CUBE IP LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080015369-A1 | Batch, semi-continuous or continuous hydrochlorination of glycerin with reduced volatile chlorinated hydrocarbon by-products and chloracetone levels | BLUE CUBE IP LLC | 2008-01-17 | — | — | US | disclosed |
| US-20080015370-A1 | Process for the conversion of a crude glycerol, crude mixtures of naturally derived multicomponent aliphatic hydrocarbons or esters thereof to a chlorohydrin | BLUE CUBE IP LLC | 2008-01-17 | — | — | US | disclosed |
| EP-1771403-A1 | CONVERSION OF A MULTIHYDROXYLATED-ALIPHATIC HYDROCARBON OR ESTER THEREOF TO A CHLOROHYDRIN | Dow Gloval Technologies Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006020234-A1 | CONVERSION OF A MULTIHYDROXYLATED-ALIPHATIC HYDROCARBON OR ESTER THEREOF TO A CHLOROHYDRIN | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015370-A1 | Process for the conversion of a crude glycerol, crude mixtures of naturally derived multicomponent aliphatic hydrocarbons or esters thereof to a chlorohydrin | GK, CETP, CYP46A1 | HDAC3 2273/4885HDAC1 3645/4885HDAC2 2287/4885 |
| US-20080045728-A1 | Conversion of a Multihydroxylated-Aliphatic Hydrocarbon or Ester Thereof to a Chlorohydrin | CHN2, HDHD5, ASPH | HDAC3 1575/4885HDAC1 3066/4885HDAC2 1854/4885 |
| US-20080015369-A1 | Batch, semi-continuous or continuous hydrochlorination of glycerin with reduced volatile chlorinated hydrocarbon by-products and chloracetone levels | GK, GLI2, CHLSN | HDAC3 1840/4885HDAC1 3211/4885HDAC2 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.